Assyro AI

FDA Orange Book · active-ingredient family

Nitrofurantoin

Nitrofurantoin is approved as 2 brand and 18 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.

Reference-listed drug:FURADANTIN · NDA 009175

2

Brand (NDA)

18

Generics (ANDA)

0

Listed patents

0

Exclusivity periods

Brand (NDA) products · capsule, suspension, tablet

ProductApplicantApplicationTEApproved
FURADANTINRLD×2CASPER PHARMA LLCNDA 009175ABApproved Prior to Jan 1, 1982
FURADANTIN×2PROCTER AND GAMBLENDA 008693Approved Prior to Jan 1, 1982

Generic (ANDA) products (18)

ProductApplicantApplicationTEApproved
NITROFURANTOINANNORA PHARMAANDA 219495ABJul 02, 2025
NITROFURANTOINSOMERSET THERAPS LLCANDA 208909ABJan 14, 2025
NITROFURANTOINBIOCON PHARMAANDA 218346ABOct 28, 2024
NITROFURANTOINAUROBINDO PHARMAANDA 212607ABMay 11, 2023
NITROFURANTOINNOVITIUM PHARMAANDA 216385ABApr 14, 2023
NITROFURANTOINACTAVIS MID ATLANTICANDA 205180ABMay 03, 2016
NITROFURANTOINNOVEL LABS INCANDA 201693ABSep 08, 2014
NITROFURANTOINSTRIDES PHARMAANDA 201355ABAug 14, 2013
NITROFURANTOINAMNEAL PHARMSANDA 201679May 11, 2011
NITROFURANTOIN×2WATSON LABSANDA 084326Approved Prior to Jan 1, 1982
FURALAN×2CHARTWELL MOLECULARANDA 080017Approved Prior to Jan 1, 1982
NITROFURANTOIN×2ELKINS SINNANDA 080003Approved Prior to Jan 1, 1982
NITROFURANTOIN×2IVAX SUB TEVA PHARMSANDA 080078Approved Prior to Jan 1, 1982
NITROFURANTOIN×2SANDOZANDA 080043Approved Prior to Jan 1, 1982
NITROFURANTOIN×2WATSON LABSANDA 080447Approved Prior to Jan 1, 1982
NITROFURANTOINWATSON LABSANDA 085797Approved Prior to Jan 1, 1982
NITROFURANTOINWATSON LABSANDA 085796Approved Prior to Jan 1, 1982
NITROFURANTOINWHITEWORTH TOWN PLSNANDA 084085Approved Prior to Jan 1, 1982

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Nitrofurantoin — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.